Integra Lifesciences Holdings (IART) Common Equity (2009 - 2026)

Integra Lifesciences Holdings' Common Equity history runs 18 years deep, the most recent figure standing at $1.0 billion for Q1 2026.

• In Q1 2026, Common Equity fell 31.61% year-over-year to $1.0 billion; the TTM figure through Mar 2026 stood at $1.0 billion (down 31.61% YoY), while the FY2025 annual figure was $1.0 billion, down 32.47% from the prior year.
• Common Equity came in at $1.0 billion for Q1 2026 at Integra Lifesciences Holdings, roughly flat from $1.0 billion in the prior quarter.
• In the past five years, Common Equity ranged from a high of $1.8 billion in Q4 2022 to a low of $1.0 billion in Q3 2025.
• A 5-year average of $1.5 billion and a median of $1.6 billion in 2023 frame the typical range for Common Equity.
• Across the five-year window, Common Equity grew 7.1% in 2022 and tumbled 32.47% in 2025, its largest moves.
• Integra Lifesciences Holdings' Common Equity stood at $1.8 billion in 2022, then fell by 12.0% to $1.6 billion in 2023, then dropped by 2.68% to $1.5 billion in 2024, then sank by 32.47% to $1.0 billion in 2025, then retreated by 0.1% to $1.0 billion in 2026.
• According to Business Quant data, Common Equity over the past three periods registered $1.0 billion, $1.0 billion, and $1.0 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison